plecanatide sold brand name trulance medication treatment chronic idiopathic constipation irritable bowel syndrome launched india brand name plecasoft gromaxx zuventus health care ltd india plecanatide agonist guanylate cyclasec plecanatide increases intestinal transit fluid buildup plecanatide acid peptide structurally identical human uroguanylin exception singleamino acid substitution plecanatide guanylate cyclasec gcc agonist molecular weight daltons structural formula chemical name lleucine lasparaginyllαaspartyllαglutamyllcysteinyllαglutamyllleucyllcysteinyllvalyllasparaginyllvalyllalanyllcysteinyllthreonylglycyllcysteinyl cyclic january plecanatide approved united states treatment chronic idiopathic constipation later also approved irritable bowel syndrome constipation presence condition determined using rome iii diagnostic criteria chronic constipation requires patient meet stool frequency stool consistency incomplete evacuation straining requirements addition likely candidate irritable bowel symptoms also present least three last six months establish chronic nature condition treatment plecanatide plecanatide shown safe effective shown least equally effective main competitor linaclotide brand name linzess shown lower rate diarrhea adverse drug recommended dosage plecanatide mg taken mouth daily plecanatide tablet taken without food swallowed whole adults swallowing difficulties plecanatide tablets crushed administered orally either apple sauce water administered water via nasogastric gastric feeding tube plecanatide shown safe effective persons years years use plecanatide persons age poses serious dehydration risk studies demonstrated plecanatide cause death juvenile mice due dehydrating use plecanatide also contraindicated persons suspected mechanical gastrointestinal plecanatide amino acid peptide amino acid sequence oneletter sequence ndecelcvnvactgcl plecanatide nearly structurally identical human uroguanylin apart substitution disulfide bonds exist well plecanatide two important motifs first acidic residues modulate affinity receptor response environmental simulations predict optimal activity plecanatide occur ph making suitable targeting cells within proximal intestine ph second actgc motif residues region responsible binding receptor guanylate plecanatide works laxative drawing water gastrointestinal tract thereby softening stool encouraging natural passage similar endogenous counterpart plecanatide activates guanylate cyclasec endothelial cells within gastrointestinal activation guanylate cyclasec catalyses production second messenger guanosine cyclic monophosphate cgmp leads protein kinase pka protein kinase g ii pkgiimediated phosphorylation cystic fibrosis transmembrane conductance regulator cftr cftr anion channel upon activation secrete negatively charged ions particularly chloride bicarbonate gi tract disruption electrochemical gradient part rectified passive secretion positively charged sodium ions lumen water follows plecanatide also known antinociceptive effect animal models however exact mechanism action yet fully suggested may part antiinflammatory action guanylate cyclasec inhibition proinflammatory cytokines inhibition associated sensory plecanatide acts receptors present apical side endothelial cells lining gastrointestinal tract able impart effect without ever entering orally ingested peptides plecanatide degraded intestinal enzymes little active drug enters systemic minimal amounts drug expected transported body concentrations plecanatide metabolites undetectable plasma following recommended dosage also shown dosages mg produced detectable concentration plecanatide human plasma time point httpsenwikipediaorgwikiplecanatide